Pharmaceutical manufacturers of Tamoxifen

Arevipharma is a modern manufacturer of active pharmaceutical ingredients and complex fine chemicals. With our products, we contribute to the health of millions of people on all continents. We are manufacturing health!

Moehs Ibérica is the headquarters of the MOEHS Group. Moehs Ibérica currently has 138 employees in the following departments: Accounting/Treasury, Purchasing/Logistics, Sales/Marketing, Human Resources, IT, Quality Assurance/Regulatory Affairs, Research and Intellectual Property. It provides services to the entire group and each of its subsidiaries. In addition, it has its own R&D building with all its services and a plant dedicated to the production of small quantities of ingredients for the pharmaceutical industry, as well as a plant for the manufacture of High Potency Active Ingredients.

OLON Group is a prominent worldwide firm specializing in the creation and manufacture of active pharmaceutical ingredients for CDMO and Generics. It serves as a dependable and preferred partner for the pharmaceutical, biotech, and specialty ingredients sectors. With a 2021 turnover of 580 million dollars, OLON provides 300 APIs for the Generic market. The company benefits from a workforce of 2,300 employees, including a highly skilled R&D team of over 300 individuals. This enables OLON to offer comprehensive integrated packages and services to facilitate the full development of APIs, leveraging extensive expertise in both Chemical and Biological processes, all within a full cGMP and regulatory framework. OLON holds approximately 160 active US DMFs and 79 granted CoS. OLON's headquarters is located in Rodano, near Milan, Italy, and it operates 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in the USA, and 1 in India. These facilities are designed in accordance with the most stringent international standards. Additionally, OLON has 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA), and Shanghai (China).

FAREVA stands as a prominent global pharmaceutical CDMO with leading expertise in the development and production of a wide variety of Drug Products and Active Pharmaceutical Ingredients (APIs). The company has a workforce of 13,000 individuals spread across 41 manufacturing facilities situated in 13 countries across EMEA and the Americas. Among these facilities, 18 are exclusively dedicated to pharmaceutical operations. FAREVA’s API division carries out its activities in 3 European locations situated in France and Germany.

Egis Pharmaceuticals PLC is a prominent generic pharmaceutical firm engaged primarily in Central and Eastern Europe. The company's operations encompass all aspects of the pharmaceutical value chain from research and development to the manufacturing of APIs and final products, as well as sales and marketing in over 60 nations. Egis possesses extensive expertise in the advancement of value-added generic compounds, effective production processes, reliable analytical techniques for impurity determination, comprehensive understanding of organic chemical reactions, and robust IP support.

Astellas Pharma Inc. is dedicated to realizing its corporate mission of enhancing global health by developing and delivering innovative and dependable pharmaceutical products. The company is committed to supporting patients worldwide by continually producing groundbreaking and highly effective medications for diseases with significant unmet medical needs through its research and development endeavors.

Yangtze River Pharmaceutical Group, also known as YRPG, is a major pharmaceutical conglomerate based in China that was established in 1971. As of July 2019, YRPG spans over 3 million square meters and operates 14 manufacturing subsidiaries situated in various areas including Beijing, Shanghai, Nanjing, and Guangzhou. It has also established research and development as well as production facilities for innovative chemical medicine and traditional patented products.

Shree Venkatesh International Limited has established itself as a rapidly growing and distinguished Indian company dedicated to the production, promotion, and export of Hormonal products. Our state-of-the-art facility is equipped with advanced technologies specifically designed for a wide range of Gynecological, IVFs, and Contraceptives Hormonal products. At Shree Venkatesh International Limited, we tirelessly strive to develop highly efficient and safe hormonal products and make them accessible at the most competitive prices globally. Our portfolio includes Injectables, lyophilized powder, and hormonal Oral tablets, contributing to the enhancement of reproductive health on a global scale. Our WHO-GMP (India) plant has been inspected and approved by regulatory bodies in Yemen (SBDMA), Kenya (PPB), Nigeria (NAFDAC), Cambodia, and the Philippines. We have plans to extend our product reach to countries in the CIS, African, Southern Asian, Southern American, PIC/s, and MENA regions. For further information, please visit www.shreevenkatesh.com. Shree Venkatesh International Limited is an ISO9001:2008 Certified company registered under the Registrar of Companies Act, specializing in the export of Generic Medicines, Pharmaceutical formulations, and Bulk drugs from India. The company is based in Gujarat, which is renowned as the Manufacturing Hub for Pharmaceutical formulations in India.

Founded in 1953, Chemische Fabrik Berg GmbH transitioned from manufacturing basic barbiturates to positioning itself as a recognized supplier of intricate molecules requiring multi-stage synthesis on the global stage. Renowned in the supplier markets for human and veterinary pharmaceuticals, we specialize in the production of APIs, controlled substances, and advanced intermediates.

Established in 1999, Asymchem (PRC stock code:002821.SZ) is an international integrated Contract Development and Manufacturing Organization (CDMO) that offers drug R&D and production services for leading pharmaceutical and biotechnology firms. Their objective is to promote more intelligent, eco-friendly, and cost-efficient manufacturing processes to aid clinical research and commercialization efforts